JIPOAd
ESID
TCR
  • Users Online: 122
  • Print this page
  • Email this page
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2020| January-March  | Volume 3 | Issue 1  
    Online since February 21, 2020

 
 
  Archives   Previous Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
GUIDELINE AND CONSENSUS
Highlights on the management of oligometastatic disease
Salem M Alshehri, Khaled Alkattan, Ahmed Abdelwarith, Hussain Alhussain, Shaker Shaker, Majed Alghamdi, Hossam Alassaf, Ali Albargawi, Manal Al Naimi, Ameen Alomair, Saif Althaqfi, Adnan Alhebshi, Majid Alothman, AbdulRahman Jazieh
January-March 2020, 3(1):34-44
DOI:10.4103/JIPO.JIPO_24_19  
  1,069 160 -
REVIEW ARTICLES
Immune checkpoint blockade in gastrointestinal cancers: The current status and emerging paradigms
Mihailo Miljanic, Anna Capasso, Todd A Triplett, S Gail Eckhardt, Kyaw L Aung
January-March 2020, 3(1):3-15
DOI:10.4103/JIPO.JIPO_1_20  
  480 73 -
CASE REPORT
Ramucirumab and docetaxel in patients with metastatic urothelial carcinoma harboring fibroblast growth factor receptor alterations: A case series and literature review
Katherine Emilie Rhoades Smith, Emilie Elise Hitron, Greta A Russler, Deborah A Baumgarten, Mehmet Asim Bilen
January-March 2020, 3(1):23-26
DOI:10.4103/JIPO.JIPO_22_19  
  445 41 -
REVIEW ARTICLES
Bromodomain and extra-terminal (BET) domain protein inhibitors for solid tumor cancers
Martin V Nguyen, Lydia Loof, Gerald S Falchook
January-March 2020, 3(1):16-22
DOI:10.4103/JIPO.JIPO_2_20  
  428 56 -
CASE REPORT
A case report of a cutaneous mucinous reaction associated with erlotinib therapy used in the treatment of metastatic tonsillar sinus squamous cell carcinoma
Benjamin D Freemyer, Carlos A Torres-Cabala, Anisha B Patel
January-March 2020, 3(1):31-33
DOI:10.4103/JIPO.JIPO_21_19  
  446 32 -
Pneumocystis infection in two patients treated with both immune checkpoint inhibitor and corticoids
Maroun Sadek, Angela Loizidou, Annie Drowart, Sigi Van den Wijngaert, Maria Gomez-Galdon, Sandrine Aspeslagh
January-March 2020, 3(1):27-30
DOI:10.4103/JIPO.JIPO_23_19  
  376 44 -
INDUSTRY NEWS
IO360° speaker interview: Q and A with Dr. Crystal Mackall

January-March 2020, 3(1):46-46
DOI:10.4103/2666-2345.275505  
  345 18 -
LETTER TO THE EDITOR
Cancer immunotherapy for immunocompromised patients: An often ignored, yet vital puzzle
Jyoti Bajpai
January-March 2020, 3(1):1-2
DOI:10.4103/2666-2345.278414  
  238 58 -
INDUSTRY NEWS
Finding T-Cure: A CEO's vision for the future of adoptive cell immunotherapy

January-March 2020, 3(1):47-47
DOI:10.4103/2666-2345.277828  
  172 27 -
Introducing the 3rd Annual PARP and DNA Damage Response Inhibitors Summit

January-March 2020, 3(1):45-45
DOI:10.4103/2666-2345.277794  
  127 15 -